Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · IEX Real-Time Price · USD
7.96
-0.35 (-4.21%)
At close: Jul 19, 2024, 4:00 PM
8.04
+0.08 (1.01%)
Pre-market: Jul 22, 2024, 7:17 AM EDT
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $1.90M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $715.00K. In the year 2023, Iovance Biotherapeutics had annual revenue of $1.19M.
Revenue (ttm)
$1.90M
Revenue Growth
n/a
P/S Ratio
1,169.89
Revenue / Employee
$3,418
Employees
557
Market Cap
2.23B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.19M | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Patterson Companies | 6.57B |
AMN Healthcare Services | 3.48B |
QuidelOrtho | 2.86B |
Amneal Pharmaceuticals | 2.50B |
Evolent Health | 2.18B |
Privia Health Group | 1.69B |
CONMED | 1.26B |
Beam Therapeutics | 360.91M |
IOVA News
- 2 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics to Present at Upcoming Conferences and Events - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates - GlobeNewsWire
- 2 months ago - Iovance (IOVA) stock price could jump by 30% after earnings - Invezz
- 2 months ago - Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024 - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire